BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

~Estimated

~$10 – $7,500

Institut de Recherches Internationales ServierNCT05786924

Phase 1

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-…

Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung Cancer+3 more

~Estimated

~$10 – $6,250

University of California, IrvineNCT07064018

Phase 1

Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastat…

Solid TumorKRAS Mutation-Related Tumors

~Estimated

~$10 – $6,250

Georgetown UniversityNCT05661201